|
|
Board Of Directors
Claude H. Nash, Ph.D. | Chairman Dr. Nash brings to Accera more than 20 years of executive management experience in the pharmaceutical and biotechnology industries. Claude Nash is currently the President and CEO of Bloodstone Ventures plc. Previously he was the founder, CEO, and chairman of ViroPharma Inc. where he oversaw the development of several antiviral drugs, successfully raised $430M in capital and achieved a $1.2B market capitalization for the company following its Initial Public Offering. Prior to founding ViroPharma, Dr. Nash was Vice President of infectious disease and cancer research at the Schering-Plough Research Institute where he initiated new strategic technologies for drug discovery and advanced three new drugs into development. Throughout his career he has managed the research and development of more than twenty drugs in the areas of infectious diseases, cancer, hypertension and pain. In the past he worked for several large pharmaceutical companies including Sterling-Winthrop, Smith Kline & French, and Eli Lilly. He is currently a director of Adolor, Inc. Dr. Nash earned his Ph.D. degree in microbial genetics and biochemistry from Colorado State University. Mr. Hooper has nearly twenty years of executive management level experience in the biotechnology industry and broad experience in corporate and business development. Gary was recently Vice President of Business Development for Bioproducts at Genencor International. He previously served as President and CEO of Ciblex Corporation, a biotech company developing therapeutic drugs for inflammatory diseases through inhibition of cell-to-cell communication. He has held a number of executive and senior management positions at Cygnus Therapeutic Systems, Genentech and Baxter Travenol. Gary is on the Board of Directors for the University of Southern California, Scientific Advisory Council at the University of Utah, Board of Directors of Joint Venture: Silicon Valley Network, Board of Trustees for the Licensing Executives Society and executive member of the Health Care Committee, and Chairman of Silicon Valley's Technology Convergence Consortium. He received an M.B.A. degree in management from the University of Southern California. Dr. Kim is the Chief Executive Officer of POSCO BioVentures, Inc. and he is their investor representative on the Accera Board of Directors. He has more than 20 years executive management experience in the biotechnology industry including Chief Technology Officer at Akkadix Corporation and Mycogen Corporation and Director of Research at Shell Oil Co., Biomedical Ventures. He has more than 50 patents and publications, and an extensive track record of corporate deal making involving biotechnology. Dr. Kim received a Ph.D. in organic chemistry from the University of Kansas and did postdoctoral studies at the Massachusetts Institute of Technology. Steve A. Orndorff, Ph.D. | Director Dr. Orndorff is the founder, President and CEO of Accera, Inc. He has more than 25 years experience in the biotechnology industry. Previously he was President and CEO of Univera Pharmaceuticals, Inc., a privately-held drug discovery company focused on diseases of inflammation and the immune response. During his career he has had responsibility in a broad array of disciplines such as basic research, manufacturing, product development and business development at various biotechnology companies including Genex Corporation, NutraSweet, Inc., and ZeaGen, Inc. Dr. Orndorff is a past President of the Society for Industrial Microbiology and a founding board member of the Colorado BioScience Association. He received a Ph.D. in microbiology from the University of Maryland. Dr. Reichenberger has many years of financial and executive management experience in the food and nutrition industry. During a 29 year career at the world's largest food company, Nestle SA, he led different functions and overall operations in Europe, Asia, Oceania, and North and South America. Recently he was Executive Vice President and Chief Financial Officer of Nestle SA, and he served on the governing admission body at the Swiss Stock Exchange. Currently he is Founder and General Partner of Inventages WHealth Management Inc. and IVC Americas SA. Dr. Reichenberger serves on the Board of Directors for several U.S. and European biotechnology companies. He earned a Masters of Business Administration from Hochschule St. Gallen and a Ph.D. in Business Administration from Wirtschaftsuniversitaet Wien. Dr. Schier is an investment manager and partner at inventages Venture Capital GmbH in Geneva, Switzerland, actively serving on the Board of Directors for six portfolio biotechnology companies in Europe and the U.S. Previously he was an investment director for life sciences at VCH Equity Group AG, and he worked in research, product development and management at several European biotechnology companies, including Xerion Pharmaceuticals AG and MorphoSys AG. Robert received a M.S. in pharmacy and a Ph.D. in cell genetics from University of Vienna, and an M.B.A. from the European University Center for Management Studies. Dr. Schier serves on the Accera Board of Directors as the representative for inventages.
|
| Copyright 2007 Accera, Inc. Site Design by Mango Media Corp. | Privacy Policy | Terms Of Use | Site Map | Contact Us | Glossary |